Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

Journal of the American College of Cardiology

Volumn 63, Issue 23, 2014, Pages 2531-2540

  Koren, Michael J ^a   Lundqvist, Pernille ^b   Bolognese, Michael ^c   Neutel, Joel M ^d   Monsalvo, Maria Laura ^e   Yang, Jingyuan ^e   Kim, Jae B ^e   Scott, Rob ^e   Wasserman, Scott M ^e   Bays, Harold ^f  

^a Jacksonville Center for Clinical Research   (United States)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c Bethesda Health Research Center   (United States)

^d Orange County Research Center   (United States)

^e AMGEN INC   (United States)

^f LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

dyslipidemia; evolocumab; monotherapy; PCSK9 inhibition

Indexed keywords

AMINOTRANSFERASE; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PLACEBO; SUBTILISIN; TRIACYLGLYCEROL; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; LIPOPROTEIN A; PROTEIN PCSK9; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE PANCREATITIS; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FRAMINGHAM RISK SCORE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE CONTUSION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VERY ELDERLY; ADOLESCENT; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT; ABNORMAL LABORATORY RESULT; COGNITIVE DEFECT; DOSAGE SCHEDULE COMPARISON; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; APOPTOSIS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; RETROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902142901     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.03.018     Document Type: Article

References (12)

1. M.J. Koren, R. Scott, and J.B. Kim et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
3. C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, and E. Braunwald Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445
4. R. Clarke, J.F. Peden, and J.C. Hopewell et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease N Engl J Med 361 2009 2518 2528
5. M.J. Koren, D.B. Hunninghake ALLIANCE Investigators Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study J Am Coll Cardiol 44 2004 1772 1779
6. J.C. LaRosa, S.M. Grundy, and D.D. Waters et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
7. A.I.M.-H.I.G.H. Investigators, W.E. Boden, and J.L. Probstfield et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
8. A.M. Tonkin, and L. Chen Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Circulation 122 2010 850 852
9. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2013 Nov 7 [E-pub ahead of print]
10. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
11. A. Pandor, R.M. Ara, and I. Tumur et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials J Intern Med 265 2009 568 580
12. M.J. Koren, R.P. Giugliano, and F.J. Raal et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial Circulation 129 2014 234 243